Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
National Center for Research Resources (NCRR)
With
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
University of California, Los Angeles
PROTOCOL OUTLINE: This is a randomized study. Patients are stratified by bone lesion turnover and secondary hyperparathyroidism.
Patients in the first group are treated with recombinant human growth hormone subcutaneously every day for 8 months.
Patients in the second group are treated with calcitriol for 8 months, administered as a daily oral dose or an intraperitoneal dose three times a week.
Patients in the third group are treated with growth hormone and calcitriol (same dosages as above).
A control group does not receive any hormonal therapy.
Age
1–18
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
PROTOCOL ENTRY CRITERIA:
-Disease Characteristics--
End-stage renal disease undergoing continuous cycling peritoneal dialysis at the University of California at Los Angeles
-Prior/Concurrent Therapy--
No concurrent prednisone
No concurrent cytotoxic agents
At least 12 months since parathyroidectomy
-Patient Characteristics--
Other: No documented history of poor compliance with medical treatment regimens
